Company Overview
For personal use only
Canchew and Chewell patented MCGTs
for Over-the-Counter ('OTC') and Prescription markets
01.
MCGTs, using APIRX patented formulation
technology, with potential to develop as OTC
products in Australia and other jurisdictions
(U.S., EU, UK, et cetera).
02.
Phase 1 Pharmacokinetic (PK) study demonstrated
that the patented CheWell formulation led to >10x
increase in CBD bioavailability compared to the
standard CBD chewing gum delivery mechanisms.
03.
Therapeutic effect and commercial considerations
will dictate whether to administer CBD via CheWell
chewable tablet or CanChew chewing gum
dosage forms.
Incannex
04.
Data from 36 patient phase 2 proof of concept
trial observed a 50% reduction in abdominal pain
in CheWell treated Irritable bowel syndrome (IBS)
patients, supporting a therepeutic effect in IBS.
05.
Therapeutic claims from the phase 2 clinical trial and
proven high bioavailability increases marketability.
06.
International regulatory analysis being undertaken
to identify what is required for commercial launch.
07.
Potential to develop CheWell for treatment of pain
and cannabis addiction.
CBD 9ng/ml)
0,9
0.8
0,7
0,6
0.5
0,4
0,3
0,2
0,1
0
0
10
Bioavailability CheWell vs Chewingum
20
30
40
CheWell 10 mg cbd (ng/ml)
50
Time (min)
60
Lead Assets
….…...0000
70
08
Chewinggum 10 mg CBD (ng/ml)
1) Analysis of CheWell shows an early onset and 10-fold higher CBD bioavailability
than a non-microencapsulated chewing gum.
Improved bioavailability means that even small doses of
CBD within MCGTS could be highly effective even without
a prescription from a doctor. That is, they would meet the
TGA requirements for an OTC product.
Increased bioavailability also reduces cost of goods,
which increases margins.
First marketing claim could be for IBS, however, could
be suitable for a range of indications for which CBD
may currently assist patients.
90
Investor Presentation
100
27View entire presentation